Document is current
Any future updates will be listed below
-
Authors
Gowda, B.H. Jaswanth https://orcid.org/0000-0003-0754-0192
Pandya, Anjali K. https://orcid.org/0000-0002-9010-0739
Gade, Shilpkala https://orcid.org/0000-0002-4312-771X
Duncan, Ross https://orcid.org/0009-0003-7502-1279
Paredes, Alejandro J. https://orcid.org/0000-0002-0414-8972
Ahmed, Mohammed Gulzar https://orcid.org/0000-0002-9226-9984
Tian, Yiwei https://orcid.org/0000-0002-3151-2565
Donnelly, Ryan F. https://orcid.org/0000-0002-0766-4147
Thakur, Raghu Raj Singh https://orcid.org/0000-0001-7582-2082
Vora, Lalitkumar K. https://orcid.org/0000-0001-8106-9066
-
Funding
Funding for this research was provided by:
Commonwealth Scholarship Commission (Commonwealth Scholarship Commission)
- License Information
-
More Information
Article History
Received: 6 May 2025
Accepted: 16 November 2025
First Online: 9 December 2025
Declarations
:
: Not applicable.
: The term “microneedles” encompasses several distinct technologies. Ryan F. Donnelly, through his university, has licensed patents on specific microneedle platforms to individual companies and has provided consultancy advice to companies developing microneedle-based products on a case-by-case basis. The microneedle systems described in this manuscript are not covered by any patent (out-licensed or otherwise) held by Ryan F. Donnelly, nor does he provide consultancy advice to any company developing microneedle technologies for ocular delivery of voriconazole or any other antifungal drug. Accordingly, Ryan F. Donnelly declares no conflict of interest in relation to this work. The other authors declare no conflict of interest.
